Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 2/20 | 0.35 |
| ▸ | HRH1 | P35367 | 2/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.30 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16341562 | 0.68 | ALDH1A1 (0.55) | — | |
| SCHEMBL15017800 | 0.63 | ADRA1A (0.41) | HRH3 | |
| SCHEMBL16003607 | 0.63 | PDE10A (0.49) | — | |
| Hydrochloric Acid SCHEMBL29997143 | 0.62 | ADRA1A (0.40) | HRH3 | |
| SCHEMBL20766130 | 0.60 | CYP19A1 (0.32) | — | |
| SCHEMBL30929230 | 0.60 | AKT2 (0.34) | HRH3 | |
| SCHEMBL7391451 | 0.58 | CTSS (0.54) | HRH3 | |
| SCHEMBL17687600 | 0.58 | PANK3 (0.48) | HRH3CHEK1 | |
| SCHEMBL25103430 | 0.55 | AKT2 (0.32) | HRH3 | |
| SCHEMBL24493227 | 0.55 | P2RX7 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220185816-A1 | JAK KINASE INHIBITOR, PREPARATION METHOD FOR SAME, AND APPLICATIONS THEREOF IN FIELD OF MEDICINE | SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO., LTD (CN) | 2022-06-16 | — | — | US | disclosed |
| EP-3939979-A1 | JAK KINASE INHIBITOR, PREPARATION METHOD FOR SAME, AND APPLICATIONS THEREOF IN FIELD OF MEDICINE | Shanghai Synergy Pharmaceutical Sciences Co., Ltd (CN) | 2022-01-19 | — | — | EP | disclosed |
| WO-2020182159-A1 | JAK KINASE INHIBITOR, PREPARATION METHOD FOR SAME, AND APPLICATIONS THEREOF IN FIELD OF MEDICINE | 上海华汇拓医药科技有限公司 | 2020-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220185816-A1 | JAK KINASE INHIBITOR, PREPARATION METHOD FOR SAME, AND APPLICATIONS THEREOF IN FIELD OF MEDICINE | JAK1, JAK2, JAK3 | HRH2 2190/4885HRH1 2290/4885HRH3 2905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.